Applications published 14 February 2007

Published: 26-Sep-2007


Immunostimulant compsn comprising at least one toll-like receptor 7 or toll-like receptor 8 agonist and toll-like receptor 4 agonist
Sanofi Pasteur 1750707*

Combinations of substituted 1-phenyl-1,5-dihydro-pyrido-[3,2-B] indol-2-ones and other HIV inhibitors
Tibotec Pharmaceuticals 1750708*

Method for the treatment of back pain
Pain Therapeutics 1750709*

Neuroprotective properties of dextrorotatory morphinans
Kim, Hyoung-Chun; Green Cross 1750710*

Treatment of neurodegenerative and inflammatory conditions with morphinan
The Government of the United States of America, represented by the Secretary, Department of Health and Human Services 1750711*

Medicaments containing N-sulphamoyl-N"-arylpiperazines for the prophylaxis or treatment of obesity and related conditions
Solvay Pharmaceuticals 1750712*

Use of IMATINIB to treat liver disorders and viral infections
Bioniche Life Sciences 1750713*

Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
Vanderbilt University; Icos 1750714*

Methods for treating mast cell disorders
Icos 1750715*

Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin
Sloan-Kettering Institute for Cancer Research 1750716*

Controlled release pharmaceutical compsns with improved bioavailability
Rubicon Research Private 1750717*

Acyclovir formulations
Emisphere Technologies 1750718*

Treatment of diseases associated with altered level of amyloid beta peptides
Boehringer Ingelheim International 1750719*

Hepoxilins and modulators of ichythin for treating skin disorders
INSERM (Institut National de la Sante et de la Recherche Medicale); Consortium Nat. Recherche & Genomique 1750720*

Topical cromolyn formulations
Emisphere Technologies 1750721*

Novel lysophosphatidic acid receptor selective antagonists
University of Virginia Patent Foundation 1750722*

Carotenoid analogues or derivatives for the inhibition and amelioration of inflammation
Hawaii Biotech 1750723*

Method for improving cognitive function by co-administration of a GABAB receptor antagonist and an acetylcholinesterase inhibitor
The Johns-Hopkins University 1750724*

Compsns comprising mannose phosphate for vaginal treatment
Kimberly-Clark Worldwide 1750725*

Spermicidal and virucidal properties of various forms of sophorolipids
Gross, Richard A; Shah, Vishal 1750726*

Kinase modulators and methods of use
Exelixis 1750727*

Prevention of arterial restenosis with active vitamin D compounds
Novacea 1750728*

Solid dosage form of wetted heparin
Emisphere Technologies 1750729*

Treatment of hypercholesterolemia, hypertriglyceridemia and cardiovascular-related conditions using phospholipase-A2 inhibitors
Ilypsa 1750730*

Supplement containing carotenoid, nicotinamide, zinc, water soluble extract of uncaria species and method using the same
Pero, Ronlad, Giampapa, Vincent 1750731*

Cancer cell growth inhibition by black bean (phaseolus vulgaris L) extracts
Istituto Tecnologico y de Estudios Superiores de Monterrey 1750732*

Method of administering porcine B-domainless fVIII
Emory University; Octagen 1750733*

Method of preparation and use of fibrinolytic enzymes in the treatment of disease
Health Enhancement Products 1750734*

Use of an Aloysia/Vebrena/Lippia triphylla/citridora for treating chronic and/or inflammatory diseases
Anoxymer 1750735*

Uses for the extract of plant of the family asclerpidacaea
Cognis France 1750736*

Improved method for identifying peptides in a biological sample
Perkin Elmer 1750737*

Microbial biosurfactants as agents for controlling pests
Awada, Salam; Spendlove, Rex; Awada, Mohammed 1750738*

Oxygenated dibenzo-alpha-pyrone chromoproteins
Natreon 1750739*

Treatment of membrane-associated diseases and disorders using lantibiotic containing compsns
Molichem Medicines 1750740*

Methods of treating diseases with random copolymers
Peptimmune 1750741*

Oral formulations comprising bone morphogenetic proteins for treating metabolic bone diseases
GlaxoSmithKline 1750743*

Medicament for the treatment of fungal infections, particularly aspergillosis
Sigma-Tau Industrie Farmaceutiche Riunite 1750744*

Methods of inhibiting proinflammatory cytokine expression using ghrelin
The United States of America, represented by the secretary, Department of Health and Human Services 1750745*

Methods of using IL-1 antagonists to treat autoinflammatory diseases
Regeneron Pharmaceuticals 1750746*

Soluble LFA-3 polypeptide for treating viral disorders
Astellas 1750747*

You may also like